AMRX
Income statement / Annual
Last year (2023), Amneal Pharmaceuticals, Inc.'s total revenue was $2.39 B,
an increase of 8.20% from the previous year.
In 2023, Amneal Pharmaceuticals, Inc.'s net income was -$83.99 M.
See Amneal Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$2.39 B
|
$2.21 B
|
$2.09 B
|
$1.99 B
|
$1.63 B
|
$1.66 B
|
$1.03 B
|
$1.02 B
|
$866.28 M
|
$785.62 M
|
| Cost of Revenue |
$1.57 B |
$1.43 B |
$1.32 B |
$1.36 B |
$1.27 B |
$946.59 M |
$507.48 M |
$420.77 M |
$367.05 M |
$335.99 M |
| Gross Profit |
$820.57 M |
$784.71 M |
$768.97 M |
$628.39 M |
$353.00 M |
$716.40 M |
$526.18 M |
$597.46 M |
$499.23 M |
$449.63 M |
| Gross Profit Ratio |
0.34 |
0.35 |
0.37 |
0.32 |
0.22 |
0.43 |
0.51 |
0.59 |
0.58 |
0.57 |
| Research and Development
Expenses |
$167.78 M
|
$200.05 M
|
$209.56 M
|
$190.59 M
|
$202.29 M
|
$210.45 M
|
$191.94 M
|
$204.75 M
|
$136.87 M
|
$106.74 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$230.44 M
|
$109.05 M
|
$118.76 M
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$429.68 M
|
$399.70 M
|
$365.50 M
|
$326.73 M
|
$289.60 M
|
$230.44 M
|
$109.05 M
|
$118.76 M
|
$109.68 M
|
$84.62 M
|
| Other Expenses |
$18.74 M |
-$3.96 M |
$15.33 M |
$2.59 M |
$1.47 M |
$2.85 M |
-$47,000.00 |
-$669,000.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$616.19 M |
$595.79 M |
$575.07 M |
$517.31 M |
$491.89 M |
$440.89 M |
$300.98 M |
$323.50 M |
$277.81 M |
$239.64 M |
| Cost And Expenses |
$2.19 B |
$2.02 B |
$1.90 B |
$1.88 B |
$1.77 B |
$1.39 B |
$808.46 M |
$744.27 M |
$644.86 M |
$575.63 M |
| Interest Income |
-$40.81 M |
$158.38 M |
$136.33 M |
$146.00 M |
$168.21 M |
$0.00 |
$0.00 |
$0.00 |
$45.84 M |
$30.66 M |
| Interest Expense |
$210.63 M |
$158.38 M |
$136.33 M |
$146.00 M |
$168.21 M |
$143.57 M |
$71.06 M |
$55.28 M |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$229.40 M
|
$240.18 M
|
$233.41 M
|
$235.39 M
|
$207.24 M
|
$137.40 M
|
$45.94 M
|
$33.02 M
|
$25.45 M
|
$20.34 M
|
| EBITDA |
$500.78 M
|
$150.43 M
|
$450.00 M
|
$381.05 M
|
$155.20 M
|
-$19.67 M
|
$271.13 M
|
$306.97 M
|
$252.68 M
|
$243.28 M
|
| EBITDA Ratio |
0.21 |
0.2 |
0.21 |
0.18 |
0.04 |
0.25 |
0.26 |
0.3 |
0.29 |
0.31 |
| Operating Income Ratio
|
0.09
|
0.09
|
0.1
|
0.05
|
-0.08
|
-0.01
|
0.24
|
0.28
|
0.26
|
0.28
|
| Total Other
Income/Expenses Net |
-$244.64 M
|
-$153.20 M
|
-$121.35 M
|
-$126.94 M
|
$28.44 M
|
-$183.05 M
|
-$73.78 M
|
-$70.06 M
|
-$60.58 M
|
-$39.24 M
|
| Income Before Tax |
-$40.27 M |
-$248.13 M |
$31.37 M |
-$35.78 M |
-$220.24 M |
-$202.72 M |
$171.32 M |
$214.82 M |
$175.58 M |
$179.33 M |
| Income Before Tax Ratio
|
-0.02
|
-0.11
|
0.01
|
-0.02
|
-0.14
|
-0.12
|
0.17
|
0.21
|
0.2
|
0.23
|
| Income Tax Expense |
$8.45 M |
$6.66 M |
$11.20 M |
-$104.36 M |
$383.33 M |
-$1.42 M |
$2.00 M |
$5.40 M |
$4.95 M |
$1.51 M |
| Net Income |
-$83.99 M |
-$254.79 M |
$20.17 M |
$68.58 M |
-$603.57 M |
-$169.73 M |
$167.65 M |
$207.38 M |
$169.45 M |
$176.93 M |
| Net Income Ratio |
-0.04 |
-0.12 |
0.01 |
0.03 |
-0.37 |
-0.1 |
0.16 |
0.2 |
0.2 |
0.23 |
| EPS |
-0.48 |
-1.69 |
0.14 |
0.47 |
-4.57 |
-1.33 |
1.46 |
1.81 |
0.9 |
0 |
| EPS Diluted |
-0.48 |
-1.69 |
0.13 |
0.46 |
-4.57 |
-1.33 |
1.46 |
1.81 |
0.9 |
0 |
| Weighted Average Shares
Out |
$176.14 M
|
$150.94 M
|
$148.92 M
|
$147.44 M
|
$132.09 M
|
$127.25 M
|
$114.86 M
|
$114.86 M
|
$189.00 M
|
$0.00
|
| Weighted Average Shares
Out Diluted |
$176.14 M
|
$150.94 M
|
$151.82 M
|
$148.91 M
|
$132.11 M
|
$127.25 M
|
$114.86 M
|
$114.86 M
|
$189.00 M
|
$0.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
